Identification of an Anti-Integrin αvβ6 Autoantibody in Patients with Ulcerative Colitis.

Bookmark this %label%

Ulcerative colitis is the most frequent type of inflammatory bowel disease and is characterized by colonic epithelial cell damage. Although involvement of autoimmunity has been suggested in ulcerative colitis, specific […]

» Read more

Colonic epithelial-derived Selenoprotein P is the source for antioxidant-mediated protection in colitis-associated cancer.

Bookmark this %label%

Patients with inflammatory bowel disease (IBD) demonstrate nutritional selenium deficiencies and are at greater risk for colon cancer. Previously, we determined that global reduction of the secreted antioxidant selenium-containing protein, […]

» Read more

Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease.

Bookmark this %label%

The risk of serious infections associated with vedolizumab in patients with inflammatory bowel disease (IBD) is uncertain. We assessed the risk of serious infections associated with use of vedolizumab versus […]

» Read more

Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis.

Bookmark this %label%

Patients with inflammatory bowel disease (IBD) have an increased risk of colorectal cancer (CRC). We performed a systematic review and meta-analysis to identify all prognostic factors for advanced colorectal neoplasia […]

» Read more

Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease.

Bookmark this %label%

Colonoscopy is essential for optimal management of inflammatory bowel disease (IBD). However, many patients opt out due to unpleasantness related to this procedure. We investigated if Nurse Administered Propofol Sedation […]

» Read more

Impact of HIV infection on the course of inflammatory bowel disease and drug safety profile: a multicenter GETAID study.

Bookmark this %label%

Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), and human immunodeficiency virus (HIV) both impact innate and adaptive immunity in the intestinal mucosa. As it is […]

» Read more

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.

Bookmark this %label%

The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) has proposed treatment-targets in 2015 for adult IBD […]

» Read more

Single Cell Transcriptional Survey of Ileal-Anal Pouch Immune Cells from Ulcerative Colitis Patients.

Bookmark this %label%

Restorative proctocolectomy with ileal pouch-anal anastomosis is a surgical procedure in patients with ulcerative colitis refractory to medical therapies. Pouchitis, the most common complication, is inflammation of the pouch of […]

» Read more

An international multicenter real-life prospective study of electronic chromoendoscopy score PICaSSO in Ulcerative Colitis.

Bookmark this %label%

Endoscopic and Histologic remission are important goals in the treatment of ulcerative colitis (UC). We investigated the correlation of the recently developed Paddington International Virtual ChromoendoScopy ScOre( PICaSSO) and other […]

» Read more

Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials.

Bookmark this %label%

In patients with Crohn’s disease and ulcerative colitis, poor correlation between symptoms and active luminal inflammation has been well established. As a result, the field has moved towards the use […]

» Read more

Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials.

Bookmark this %label%

In patients with Crohn’s disease and ulcerative colitis, poor correlation between symptoms and active luminal inflammation has been well established. As a result, the field has moved towards the use […]

» Read more

Novel fecal biomarkers that precede clinical diagnosis of ulcerative colitis.

Bookmark this %label%

Altered gut microbiota composition and function have been associated with inflammatory bowel diseases (IBD) including ulcerative colitis (UC), but causality and mechanisms remain unknown.We applied 16S rRNA gene sequencing, shotgun […]

» Read more

Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.

Bookmark this %label%

O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation. Gut microbiota […]

» Read more

Modeling Endoscopic Improvement after Induction Treatment with Mesalamine in Patients with Mild-to-Moderate Ulcerative Colitis.

Bookmark this %label%

Endoscopic improvement is an important treatment target for mild-to-moderate ulcerative colitis (UC). However, early endoscopic evaluation is not always feasible. We aimed to develop a clinical decision support tool to […]

» Read more

Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated with Good Maternal and Fetal Outcomes.

Bookmark this %label%

Data regarding the management and outcomes of acute severe ulcerative colitis (ASUC) in pregnant patients is sparse, consisting mainly of case reports.1-3 We report on the largest cohort of pregnant […]

» Read more

Altered intestinal ACE2 levels are associated with inflammation, severe disease and response to anti-cytokine therapy in IBD.

Bookmark this %label%

The host receptor for SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2) is highly expressed in small bowel (SB). Our aim was to identify factors influencing intestinal ACE2 expression in Crohn’s disease (CD), […]

» Read more

Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn’s Disease: A Meta-Analysis of Population-based Cohorts.

Bookmark this %label%

We conducted a systematic review with meta-analysis to estimate rates and trends of colectomy in patients with ulcerative colitis (UC), and of primary and re-resection in patients with Crohn’s disease […]

» Read more

Efficacy and Safety of Extended Induction with Tofacitinib for the Treatment of Ulcerative Colitis.

Bookmark this %label%

Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). The efficacy and safety of tofacitinib were demonstrated in a dose-ranging phase 2 induction […]

» Read more

Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction.

Bookmark this %label%

Accelerated dose infliximab (IFX) induction is associated with reduced short-term colectomy rate in acute severe ulcerative colitis (ASUC). Data on medium/long-term outcomes of this strategy are limited.Evaluate medium/long-term outcomes in […]

» Read more

Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases.

Bookmark this %label%

Although Crohn’s disease (CD) and ulcerative colitis (UC) have been considered as disorders that affect individuals of European ancestry, the epidemiology of the inflammatory bowel diseases (IBDs) is changing. Coupled […]

» Read more

Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients after Initiation of Biologics: A Cohort Study.

Bookmark this %label%

50% to 80% Crohn’s disease (CD) and 10% to 30% ulcerative colitis (UC) patients require surgery over their lifetime. Biologic therapies may alter this natural history, but data on the […]

» Read more

Vedolizumab or TNF-antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: A retrospective cohort study.

Bookmark this %label%

Treatment of patients with inflammatory bowel diseases (IBD; Crohn’s disease (CD), ulcerative colitis (UC) who have a prior history of cancer pose a unique challenge. The impact of Vedolizumab (VDZ) […]

» Read more

Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.

Bookmark this %label%

The aim of this study was to describe the long-term health outcomes of children born to mothers with inflammatory bowel disease (IBD) and to assess the impact of maternal IBD […]

» Read more

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.

Bookmark this %label%

We aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice.A multicenter, retrospective, observational cohort study (May 2014 to December […]

» Read more

Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.

Bookmark this %label%

Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). The efficacy and safety of tofacitinib in patients with moderate to severe UC, up […]

» Read more

Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.

Bookmark this %label%

Cobitolimod is a topically administered, DNA-based oligonucleotide that activates Toll-like receptor 9 (TLR9), and previous research has shown clinical efficacy in patients with moderate-to-severe ulcerative colitis. Here we assessed the […]

» Read more

Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.

Bookmark this %label%

Patients with inflammatory bowel disease (IBD) often report symptoms compatible with irritable bowel syndrome (IBS), which might have an effect on psychological health. However, previous estimates of the magnitude of […]

» Read more

Treat to target: The role of histologic healing in inflammatory bowel diseases: A systematic review and meta-analysis.

Bookmark this %label%

Endoscopic remission is a recognized therapeutic endpoint in inflammatory bowel disease (IBD; Crohn’s disease (CD), ulcerative colitis (UC)). The impact of persistent histologic activity on long-term outcomes is less clear […]

» Read more

Familial Risk of Inflammatory Bowel Disease – A Population-based Cohort study in South Korea.

Bookmark this %label%

Despite the rapid rise in IBD, population-level familial risk estimates of inflammatory bowel diseases (IBD) are still lacking in Asian-Pacific countries. We aimed to quantify the familial risk of incident […]

» Read more
1 2 3 4